Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Peter VolkersKay-Martin HanschmannThierry CalvezHervé ChambostPeter W CollinsVirginie DemiguelDaniel P HartCharles R M HayJenny GoudemandRolf LjungBen P PalmerElena SantagostinoElla M van HardeveldMarijke van den BergBrigitte Keller-StanislawskiPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2019)
The trend of an increased risk of inhibitor development in PUPs for one recombinant product illustrates that extrapolation from one recombinant factor VIII product to other products might not be justified.
Keyphrases